Table III.
Bcl2 over-expression preferentially expands T1, T2 and MZ B cells in BrTg micea
| C57Bl/6 control | BrTg | Bcl2 | BrTg x Bcl2 | Average fold- increase | |
|---|---|---|---|---|---|
| Splenic cell numbers (× 106) | |||||
| Total cells | 109.6±18.5 c | 90.5±13.2 | 533.3±18.9 | 575.4±63.9 | |
| CD19+ B cells | 47.5±4.48 | 38.2.6±2.8 | 264.6±21.9 | 267.5±24.9 | |
| T1b | 5.63±0.81 | 7.39±0.76 | 14.4±2.45 | 35.7±4.22 | 2.5d |
| T2 | 8.33±1.15 | 5.12±0.47 | 34.2±6.02 | 28.0±4.68 | 0.82 |
| T3 | 2.94±0.83 | 2.41±0.49 | 20.2±4.88 | 12.1±1.65 | 0.60 |
| MZ | 2.25±0.27 | 3.69±0.32 | 7.08±2.22 | 40.1±7.17 | 5.7 |
| FO | 26.2±2.98 | 15.3±1.30 | 144.0±10.5 | 75.3±9.99 | 0.52 |
Male and female mice (n = 7 to 11 mice per group) were analyzed at 8 to 12 weeks of age.
Splenic B cell subsets were defined as in Fig 1.
Total cell numbers (MEAN±SEM) per spleen were determined by multiplying the frequency of live gated cells by total cells and are shown ×106.
Average fold increase in BrTg x Bcl2 double transgenic mice compared to Bcl2 transgenic mice was calculated by dividing the average total cell numbers for each subset.